A szelénkezelés hatása az autoimmun thyreoiditisre

Translated title of the contribution: The effect of selenium therapy on autoimmune thyroiditis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Selenium as an essential trace element is capable of exerting complex effects on the endocrine and immune system by its antioxidant capacity. The role of selenium is important because the level of free oxygen radicals is elevated in the physiological thyroid hormone synthesis. The aim of study: Was to determine whether selenium therapy can influence the level of antithyroid peroxidase and antithyroglobulin antibodies or whether there is a correlation between antioxidant capacity and the titer of autoantibodies. Method: 132 patient with autoimmune thyroiditis were investigated in a prospective, blind and placebo-controlled study. L-thyroxine substitution therapy was made in both groups and the level of TSH remained in the normal range. The selenium-treated group (n = 70 patients, 68 female, mean age 41,4 ± 9,5 year) was compared with the placebo-treated group (n = 62 patients, 61 female, mean age 42,7 ± 8,3 year). Selenium therapy was continued by L-seleno-methionine (per os 2 × 100 μg/day) for one year. Determination of TSH, fT4, fT3 and autoantibodies was carried out by chemiluminescence method. Total antioxidant capacity was determined by Randox kit, the level of selenium in the sera by atomic absorption technique was measured. In the follow-up study, patients were controlled every third month and at the end of a one-year observation period. Results: The level of selenium in the untreated patients was significantly lower than in treated patients and controls. The fT3/fT4 ration proved to be higher in patients after selenium therapy. The titer of antithyroid antibodies (mostly the antithyroid peroxidase) significantly decreased at the end of the study. An inverse correlation was found between antioxidant capacity and the level of antithyroid peroxidase antibodies. The volume of thyroid gland slightly diminished in treated patients. Side effects were not observed. Conclusions: Selenium completed with L-thyroxine is a suitable therapy for patients with autoimmune thyroiditis.

Original languageHungarian
Pages (from-to)1227-1232
Number of pages6
JournalOrvosi Hetilap
Volume149
Issue number26
DOIs
Publication statusPublished - Jun 29 2008

Fingerprint

Autoimmune Thyroiditis
Selenium
Antioxidants
Peroxidase
Therapeutics
Thyroxine
Autoantibodies
Placebos
Endocrine System
Antibodies
Trace Elements
Luminescence
Thyroid Hormones
Methionine
Free Radicals
Immune System
Reactive Oxygen Species
Thyroid Gland
Reference Values
Observation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A szelénkezelés hatása az autoimmun thyreoiditisre. / Balázs, C.

In: Orvosi Hetilap, Vol. 149, No. 26, 29.06.2008, p. 1227-1232.

Research output: Contribution to journalArticle

@article{ea23a8678198400183b7523e476786a4,
title = "A szel{\'e}nkezel{\'e}s hat{\'a}sa az autoimmun thyreoiditisre",
abstract = "Selenium as an essential trace element is capable of exerting complex effects on the endocrine and immune system by its antioxidant capacity. The role of selenium is important because the level of free oxygen radicals is elevated in the physiological thyroid hormone synthesis. The aim of study: Was to determine whether selenium therapy can influence the level of antithyroid peroxidase and antithyroglobulin antibodies or whether there is a correlation between antioxidant capacity and the titer of autoantibodies. Method: 132 patient with autoimmune thyroiditis were investigated in a prospective, blind and placebo-controlled study. L-thyroxine substitution therapy was made in both groups and the level of TSH remained in the normal range. The selenium-treated group (n = 70 patients, 68 female, mean age 41,4 ± 9,5 year) was compared with the placebo-treated group (n = 62 patients, 61 female, mean age 42,7 ± 8,3 year). Selenium therapy was continued by L-seleno-methionine (per os 2 × 100 μg/day) for one year. Determination of TSH, fT4, fT3 and autoantibodies was carried out by chemiluminescence method. Total antioxidant capacity was determined by Randox kit, the level of selenium in the sera by atomic absorption technique was measured. In the follow-up study, patients were controlled every third month and at the end of a one-year observation period. Results: The level of selenium in the untreated patients was significantly lower than in treated patients and controls. The fT3/fT4 ration proved to be higher in patients after selenium therapy. The titer of antithyroid antibodies (mostly the antithyroid peroxidase) significantly decreased at the end of the study. An inverse correlation was found between antioxidant capacity and the level of antithyroid peroxidase antibodies. The volume of thyroid gland slightly diminished in treated patients. Side effects were not observed. Conclusions: Selenium completed with L-thyroxine is a suitable therapy for patients with autoimmune thyroiditis.",
keywords = "Antithyroid pcroxidase enzyme antibodies, Autoimmune thyroiditis, Selenium, Total antioxidant capacity",
author = "C. Bal{\'a}zs",
year = "2008",
month = "6",
day = "29",
doi = "10.1556/OH.2008.28408",
language = "Hungarian",
volume = "149",
pages = "1227--1232",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "26",

}

TY - JOUR

T1 - A szelénkezelés hatása az autoimmun thyreoiditisre

AU - Balázs, C.

PY - 2008/6/29

Y1 - 2008/6/29

N2 - Selenium as an essential trace element is capable of exerting complex effects on the endocrine and immune system by its antioxidant capacity. The role of selenium is important because the level of free oxygen radicals is elevated in the physiological thyroid hormone synthesis. The aim of study: Was to determine whether selenium therapy can influence the level of antithyroid peroxidase and antithyroglobulin antibodies or whether there is a correlation between antioxidant capacity and the titer of autoantibodies. Method: 132 patient with autoimmune thyroiditis were investigated in a prospective, blind and placebo-controlled study. L-thyroxine substitution therapy was made in both groups and the level of TSH remained in the normal range. The selenium-treated group (n = 70 patients, 68 female, mean age 41,4 ± 9,5 year) was compared with the placebo-treated group (n = 62 patients, 61 female, mean age 42,7 ± 8,3 year). Selenium therapy was continued by L-seleno-methionine (per os 2 × 100 μg/day) for one year. Determination of TSH, fT4, fT3 and autoantibodies was carried out by chemiluminescence method. Total antioxidant capacity was determined by Randox kit, the level of selenium in the sera by atomic absorption technique was measured. In the follow-up study, patients were controlled every third month and at the end of a one-year observation period. Results: The level of selenium in the untreated patients was significantly lower than in treated patients and controls. The fT3/fT4 ration proved to be higher in patients after selenium therapy. The titer of antithyroid antibodies (mostly the antithyroid peroxidase) significantly decreased at the end of the study. An inverse correlation was found between antioxidant capacity and the level of antithyroid peroxidase antibodies. The volume of thyroid gland slightly diminished in treated patients. Side effects were not observed. Conclusions: Selenium completed with L-thyroxine is a suitable therapy for patients with autoimmune thyroiditis.

AB - Selenium as an essential trace element is capable of exerting complex effects on the endocrine and immune system by its antioxidant capacity. The role of selenium is important because the level of free oxygen radicals is elevated in the physiological thyroid hormone synthesis. The aim of study: Was to determine whether selenium therapy can influence the level of antithyroid peroxidase and antithyroglobulin antibodies or whether there is a correlation between antioxidant capacity and the titer of autoantibodies. Method: 132 patient with autoimmune thyroiditis were investigated in a prospective, blind and placebo-controlled study. L-thyroxine substitution therapy was made in both groups and the level of TSH remained in the normal range. The selenium-treated group (n = 70 patients, 68 female, mean age 41,4 ± 9,5 year) was compared with the placebo-treated group (n = 62 patients, 61 female, mean age 42,7 ± 8,3 year). Selenium therapy was continued by L-seleno-methionine (per os 2 × 100 μg/day) for one year. Determination of TSH, fT4, fT3 and autoantibodies was carried out by chemiluminescence method. Total antioxidant capacity was determined by Randox kit, the level of selenium in the sera by atomic absorption technique was measured. In the follow-up study, patients were controlled every third month and at the end of a one-year observation period. Results: The level of selenium in the untreated patients was significantly lower than in treated patients and controls. The fT3/fT4 ration proved to be higher in patients after selenium therapy. The titer of antithyroid antibodies (mostly the antithyroid peroxidase) significantly decreased at the end of the study. An inverse correlation was found between antioxidant capacity and the level of antithyroid peroxidase antibodies. The volume of thyroid gland slightly diminished in treated patients. Side effects were not observed. Conclusions: Selenium completed with L-thyroxine is a suitable therapy for patients with autoimmune thyroiditis.

KW - Antithyroid pcroxidase enzyme antibodies

KW - Autoimmune thyroiditis

KW - Selenium

KW - Total antioxidant capacity

UR - http://www.scopus.com/inward/record.url?scp=48049094747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049094747&partnerID=8YFLogxK

U2 - 10.1556/OH.2008.28408

DO - 10.1556/OH.2008.28408

M3 - Article

VL - 149

SP - 1227

EP - 1232

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 26

ER -